Title |
Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts
|
---|---|
Published in |
BMC Cancer, September 2013
|
DOI | 10.1186/1471-2407-13-400 |
Pubmed ID | |
Authors |
Sherrill L Macura, Jeremy L Steinbacher, Maximilian B MacPherson, Melissa J Lathrop, Mutlay Sayan, Jedd M Hillegass, Stacie L Beuschel, Timothy N Perkins, Page C Spiess, Albert van der Vliet, Kelly J Butnor, Arti Shukla, Marilyn Wadsworth, Christopher C Landry, Brooke T Mossman |
Abstract |
Malignant mesotheliomas (MMs) are chemoresistant tumors related to exposure to asbestos fibers. The long latency period of MM (30-40 yrs) and heterogeneity of tumor presentation make MM difficult to diagnose and treat at early stages. Currently approved second-line treatments following surgical resection of MMs include a combination of cisplatin or carboplatin (delivered systemically) and pemetrexed, a folate inhibitor, with or without subsequent radiation. The systemic toxicities of these treatments emphasize the need for more effective, localized treatment regimens. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
India | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 3% |
Portugal | 1 | 3% |
Unknown | 37 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 11 | 28% |
Researcher | 9 | 23% |
Student > Master | 5 | 13% |
Other | 3 | 8% |
Student > Bachelor | 2 | 5% |
Other | 3 | 8% |
Unknown | 6 | 15% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 10 | 26% |
Medicine and Dentistry | 6 | 15% |
Biochemistry, Genetics and Molecular Biology | 3 | 8% |
Engineering | 3 | 8% |
Immunology and Microbiology | 2 | 5% |
Other | 7 | 18% |
Unknown | 8 | 21% |